BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

12:00 AM
Dec 05, 2011
 |  BC Week In Review  |  Clinical News  |  Regulatory

Vectibix panitumumab regulatory update

The U.K.'s NICE issued a final appraisal determination recommending against 3 second-line therapies for metastatic colorectal cancer (mCRC). The products are Erbitux cetuximab from Merck KGaA (Xetra:MRK, Darmstadt, Germany); Avastin bevacizumab from Roche (SIX:ROG; OTCQX:RHHBY, Basel, Switzerland); and Vectibix panitumumab from Amgen. NICE said there were uncertainties in the evidence for the drugs' effectiveness. The decision is in line with a September preliminary appraisal (see BioCentury, Sept. 12).

NICE said...

Read the full 371 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >